The Mount Sinai Conference on the pharmacotherapy of schizophrenia

Stephen R. Marder, Susan M. Essock, Alexander L. Miller, Robert W. Buchanan, John M. Davis, John M. Kane, Jeffrey Lieberman, Nina R. Schooler

Research output: Contribution to journalArticlepeer-review

121 Scopus citations


This report summarizes the recommendations from a consensus meeting that focused on specific questions regarding the pharmacotherapy of schizophrenia. The issues were selected because there was evidence that experts had recently disagreed about the evidence supporting a particular practice or when there were substantial variations in a clinical practice indicating that there was disagreement among clinicians. The group of experts was able to reach a consensus regarding the evidence base pertaining to the following issues: First generation (FGAs) and second generation (SGAs) antipsychotics as first line agents; the duration of antipsychotic trials; the effectiveness of clozapine and other agents for treatment refractory schizophrenia; risk of tardive dyskinesia on FGAs and SGAs; differences among antipsychotics for different dimensions of psychopathology; and side effect monitoring for various antipsychotics.

Original languageEnglish (US)
Pages (from-to)5-16
Number of pages12
JournalSchizophrenia bulletin
Issue number1
StatePublished - 2002
Externally publishedYes


  • Antipsychotics
  • Clozapine
  • Evidence-based practice
  • Schizophrenia
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'The Mount Sinai Conference on the pharmacotherapy of schizophrenia'. Together they form a unique fingerprint.

Cite this